SLC5A2 and type 2 diabetes mellitus: Cardiorenal benefits of sodium-glucose cotransporter 2 inhibitors (SGLT2is) have been demonstrated in large-scale clinical trials in patients with type 2 diabetes and either with an established cardiovascular disease or multiple cardiovascular risk factors [1-3].